rightdx/iStock via Getty Images
Aktis Oncology (AKTS) is a clinical-stage developer of radiopharmaceuticals for the treatment of cancer. Their competitive edge is a proprietary mini-protein platform with an attached radioisotope that enables the precise targeting of the
Analyst’s Disclosure: I/we have a beneficial long position in the shares of AKTS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
I am not a registered financial advisor, and this article is for informational and educational purposes only. It does not constitute financial, investment, or trading advice. Biotechnology investing carries extreme binary risk, and clinical trial failures can result in total loss of capital.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。